To OTC Journal Members:
 

Calypte Biomed (OTC BB: CALY): Interview Next Week With Chairman Tony Cataldo

As you can see from the chart, Calypte Biomed has been quite volatile over the past two months. Today, on the strength of another press release concerning additional distribution of their test kits, the stock traded huge volume, 14.3 million shares. 

The company recently announced Planned Parenthood had become a customer (click here), and today announced their test kits would be used at the upcoming 14th annual Black Church Week of Prayer for the Healing of AIDS, the nation's largest AIDS awareness program targeting African Americans, kicking off in New York City February 28, 2003 (click here).

If history repeats itself, the stock could rebound off the $.05 level as it has done twice in the past. Traders may want to step up to the plate at current levels as the stock has now put in a bullish "triple bottom".

In a recent conference call covering year end numbers and fundamental developments, it was revealed Calypte had also obtained three new insurance company clients, including the one major overseas customer.

Despite many fundamental accomplishments over the past six months, shares of Calypte Biomed are trading at the low end of their trading range. This stock is typically one of the highest volume stocks on the OTC Bulletin Board every day, and would no doubt be trading higher if the supply of shares were diminished.

In fact, the OTC Journal first reported on this company on May 31, 2002. At the time the stock was trading at $.13. There were 60 million shares issued and outstanding, and the market value of the company was $7.8 million.

Today, Calypte Biomed probably has 200 million to 220 million shares issued and outstanding. In addition, shareholders recently approved the number of authorized shares to be increased to 800 million.

Therefore, today's market value of the company, based on the $.05 market price, is $11 million. Despite the stock being at 40% of the price in our original trading alert, the company's market value is 41% greater than it was on that date.

We have invited Calypte Chairman Tony Cataldo to discuss this issue and fundamental corporate developments in an interview. We will conduct the interview early next week and publish either Wednesday or Thursday.

If the company can continue to move forward as it has, and the supply of stock abates, investors could do very well off current levels. The interview will be streamed over the internet and published in text form.

SwingWire.com also has a lucrative incentive model for experienced investors and traders who consistently outperform the market. Share market ideas with other like-minded investors, establish a proven track record, provide insightful commentary, attract followers and ultimately become one of the Internet's highest paid and most sought after CyberAnalysts! 

Click here to receive your FREE 30-Day Trial Membership with no further obligation. Sign Up Today! 
 

Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts.

MarketByte LLC has been paid a fee of 250,000 free trading shares of Calypte common stock by First Stage Capital for coverage of Calypte Biomed. On August 12, 2002, MarketByte LLC entered into an agreement directly with Calypte Biomed to continue coverage of the company through October 31, 2002. Calypte Biomed paid $25,000 cash as compensation, and an additional 300,000 shares of free trading stock were paid by a third party on behalf of the company. On November 1, 2002, MarketByte LLC and Calypte Biomed to agreed to renew the agreement to extend through January 31, 2003 in return for $25,000 in cash, and an additional 300,000 shares of free trading stock were paid by a third party. Please review our policy on selling shares found in the Mission Statement on our home page.

All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

The profiles, critiques, and other editorial content of the OTCjournal.com may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.